Federal Register / Vol. 72, No. 96 / Friday, May 18, 2007 / Notices 28073 

DEA has considered the factors in 21 

U.S.C. 823(a) and determined that the 

registration of Chattem Chemicals, Inc. 

to manufacture the listed basic classes 

of controlled substances is consistent 

with the public interest at this time. 

DEA has investigated Chattem 

Chemicals, Inc. to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with State and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: May 14, 2007. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E7–9644 Filed 5–17–07; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on July 28, 2006, Cody 

Laboratories, Inc., 601 Yellowstone 

Avenue, Cody, Wyoming 82414, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedule I and II: 

Drug Schedule 

Dihydromorphine (9145) ............... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Amobarbital (2125) ....................... II 

Pentobarbital (2270) ..................... II 

Secobarbital (2315) ...................... II 

Cocaine (9041) ............................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Diphenoxylate (9170) ................... II 

Meperidine (9230) ........................ II 

Oxymorphone (9652) ................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The company plans on manufacturing 

the listed controlled substance in bulk 

for sale to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to bulk manufacture such a 

substance, may file comments or 

objections to the issuance of the 

proposed registration pursuant to 21 

CFR 1301.33(a). 

Any such written comments or 

objections being sent via regular mail 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register 

Representative(ODL), Washington, DC 

20537, or any being sent via express 

mail should be sent to Drug 

Enforcement Administration, Office of 

Diversion Control, Federal Register 

Representative(ODL), 2401 Jefferson 

Davis Highway, Alexandria, Virginia 

22301; and must be filed no later than 

July 17, 2007. 

Dated: May 10, 2007. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E7–9608 Filed 5–17–07; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated February 5, 2007 and 

published in the Federal Register on 

February 12, 2007, (72 FR 6578–6579), 

Fisher Clinical Services Inc., 7554 

Schantz Road, Allentown, Pennsylvania 

18106, made application by letter to the 

Drug Enforcement Administration 

(DEA) to be registered as an importer of 

Noroxymorphone (9668), a basic class of 

controlled substance listed in schedule 

II. 

The company plans to import the 

listed controlled substance for analytical 

research and clinical trials. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

Fisher Clinical Services Inc. to import 

the basic class of controlled substance is 

consistent with the public interest and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971, at 

this time. DEA has investigated Fisher 

Clinical Services Inc. to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with State and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic class of controlled substance 

listed. 

Dated: May 14, 2007. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E7–9610 Filed 5–17–07; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated November 21, 2006 

and published in the Federal Register 

on December 1, 2006, (71 FR 69590), 

Formulation Technologies LLC, 11400 

Burnet Road, Suite 4010, Austin, Texas 

78758, made application to the Drug 

Enforcement Administration (DEA) to 

be registered as an importer of Fentanyl 

(9801), a basic class of controlled 

substance listed in schedule II. 

The company plans to import the 

listed controlled substance for clinical 

trials, research, analytical purposes and 

distribution to its customers. 

One objection was received; however, 

it has subsequently been withdrawn. 

DEA has considered the factors in 21 

U.S.C. 823(a) and 952(a) and determined 

that the registration of Formulation 

Technologies LLC to import the basic 

classes of controlled substances is 

consistent with the public interest and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971, at 

this time. DEA has investigated 

Formulation Technologies LLC to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with State and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic class of controlled substance 

listed. 


pwalker on PROD1PC71 with NOTICES
28074 Federal Register / Vol. 72, No. 96 / Friday, May 18, 2007 / Notices 

Dated: May 10, 2007. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E7–9606 Filed 5–17–07; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated December 14, 2006, 

and published in the Federal Register 

on December 22, 2006, (71 FR 77065–

77066), Johnson Matthey Inc., Custom 

Pharmaceuticals Department, 2003 

Nolte Drive, West Deptford, New Jersey 

08066, made application by letter to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of 14–

Hydroxymorphinone (9654), a basic 

class of controlled substance listed in 

schedule II. 

The company plans to manufacture 

the listed controlled substances in bulk 

as an intermediate for use in the 

production of another controlled 

substance. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Johnson Matthey Inc to manufacture the 

listed basic class of controlled substance 

is consistent with the public interest at 

this time. DEA has investigated Johnson 

Matthey Inc to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with State and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic class of controlled substance 

listed. 

Dated: May 14, 2007. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E7–9617 Filed 5–17–07; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated November 2, 2006, 

and published in the Federal Register 

on November 8, 2006, (71 FR 65544), 

Johnson Matthey Inc., Custom 

Pharmaceuticals Department, 2003 

Nolte Drive, West Deptford, New Jersey 

08066, made application by letter to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the basic classes of 

controlled substances listed in schedule 

II: 

Drug Schedule 

Nabilone (7379) ............................ II 

Noroxymorphone (9668) .............. II 

The company plans to manufacture 

the listed controlled substances in bulk 

for sales to its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Johnson Matthey Inc. to manufacture 

the listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Johnson Matthey Inc. to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with State and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: May 14, 2007. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E7–9629 Filed 5–17–07; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated December 14, 2006, 

and published in the Federal Register 

on December 22, 2006, (71 FR 77065), 

Johnson Matthey Inc., Custom 

Pharmaceuticals Department, 2003 

Nolte Drive, West Deptford, New Jersey 

08066, made application by letter to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of Remifentanil (9739), a 

basic class of controlled substance listed 

in schedule II. 

The company plans on producing this 

item for sale to its customers, who are 

final dosage manufacturers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Johnson Matthey Inc to manufacture the 

listed basic class of controlled substance 

is consistent with the public interest at 

this time. DEA has investigated Johnson 

Matthey Inc to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with State and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic class of controlled substance 

listed. 

Dated: May 9, 2007. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E7–9634 Filed 5–17–07; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated December 14, 2006, 

and published in the Federal Register 

on December 22, 2006, (71 FR 77065–

77066), Johnson Matthey Inc., Custom 

Pharmaceuticals Department, 2003 

Nolte Drive, West Deptford, New Jersey 

08066, made application by letter to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of 14–

Hydroxymorphinone (9654), a basic 

class of controlled substance listed in 

schedule II. 

The company plans to manufacture 

the listed controlled substances in bulk 

as an intermediate for use in the 

production of another controlled 

substance. 


pwalker on PROD1PC71 with NOTICES